Agenus Announces Virtual Annual Shareholders Meeting

Rhea-AI Summary

Agenus Inc. (NASDAQ: AGEN) has announced it will host its 2020 Annual Shareholders Meeting virtually on June 16, 2020, at 5:00 PM ET due to COVID-19 concerns. Shareholders can log in starting at 4:30 PM ET using a 16-digit control number provided in proxy materials. Guests may join in listen-only mode. The meeting can be accessed via the company's website or directly through the virtual meeting link. A replay will be available for one year post-event. Agenus focuses on immuno-oncology therapy development to enhance cancer treatment.

Positive

• Hosting a virtual Annual Shareholders Meeting allows for broader attendance amid COVID-19.
• Agenus is focused on advancing therapies in immuno-oncology, potentially benefiting investor confidence.

Negative

• None.

LEXINGTON, Mass., June 16, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announces that it will host its 2020 Annual Shareholders Meeting virtually due to public health concerns related to the COVID-19.

The annual meeting will begin at 5:00pm ET on June 16, 2020 and will be conducted in a virtual format only.  Registration for attendees will start at 4:30 p.m. ET

To participate in the virtual Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2020 and enter the 16-digit control number found in their proxy materials. Guests may also access the virtual Annual Shareholders Meeting but in listen-only mode. No control number is required for guests.

Webcast Information:
Date: Tuesday, June 16, 2020
Time: 5:00 p.m. ET

Live Webcast: accessible from the Company's website at https://investor.agenusbio.com/presentation-webcasts or with this link www.virtualshareholdermeeting.com/AGEN2020

A replay will be available on the Company's website after the call and will remain available for one year.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:
Agenus Inc. 
Jennifer Buell, PhD
781-674-4420 
Jennifer.Buell@agenusbio.com 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/agenus-announces-virtual-annual-shareholders-meeting-301077706.html

SOURCE Agenus Inc.

FAQ

When is the Agenus 2020 Annual Shareholders Meeting?

The meeting is scheduled for June 16, 2020, at 5:00 PM ET.

How can I attend the Agenus Annual Shareholders Meeting?

Shareholders can attend by visiting www.virtualshareholdermeeting.com/AGEN2020 and entering their control number.

What is the significance of the virtual format for Agenus's shareholders meeting?

The virtual format allows shareholders to participate safely amidst public health concerns due to COVID-19.

Will there be a replay of the Agenus shareholders meeting?

Yes, a replay will be available on the Company's website for one year after the meeting.

What is the focus of Agenus Inc.?

Agenus is focused on developing therapies that engage the body’s immune system to fight cancer and infections.